SCHEMBL2835117

SCHEMBL2835117

C#CCCCCOC(=O)c1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.50
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
MAPT P10636 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ALOX5 P09917 3/20 0.35
TDP1 Q9NUW8 1/20 0.34
RECQL P46063 1/20 0.33
NPC1 O15118 1/20 0.33
TDP2 O95551 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834274 0.95 ESR1 (0.51) ESR1CA1CA2MAPTCYP1A2
SCHEMBL2838213 0.87 ESR1 (0.46) ESR1CA1CA2HSD17B10ALOX5
SCHEMBL2835213 0.86 ESR1 (0.41) ESR1CA1CA2ALOX5TDP1
SCHEMBL13291852 0.85 ESR1 (0.63) ESR1CA1CA2MAPTTDP1
SCHEMBL17367967 0.81 ESR1 (0.63) ESR1CA1CA2HSD17B10TDP1
SCHEMBL2835351 0.81 KMT2A (0.47) MAPTALOX5TDP1NPC1MEN1
SCHEMBL2835336 0.81 ESR1 (0.42) ESR1CA1CA2ALOX5NPC1
SCHEMBL2833709 0.81 ALOX5 (0.38) ESR1MAPTCYP1A2CYP2D6CYP2C9
SCHEMBL13291857 0.78 ESR1 (0.56) ESR1CA1CA2TDP1RECQL
SCHEMBL2833604 0.77 NPC1 (0.52) ESR1CA1CA2MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 ESR1 119/4885CA1 115/4885CA2 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.